Skip to Content

KalVista Pharmaceuticals Inc KALV Stock Quote

| Rating as of

Morningstar‘s Stock Analysis KALV

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics KALV

Company Profile KALV

Business Description

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

55 Cambridge Parkway, Suite 901 East
Cambridge, MA, 02142
T +1 857 999-0075
Industry Biotechnology
Most Recent Earnings Apr 30, 2022
Fiscal Year End Apr 30, 2023
Stock Type Slow Growth
Employees 105